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ABSTRACT 
Objective: The aim of the present work was to enhance the solubility of rosuvastatin calcium by self-nano emulsifying drug delivery system 
(SNEDDS) using mixtures of oil, cosolvent, surfactant and cosurfactant. 
Methods: Based on solubility study and emulsification efficiency, Preliminary investigations of various oils, surfactants and cosurfactants were 
carried out for the selection of the proper SNEDDS ingredients. Pseudo-ternary phase diagrams were constructed to identify the efficient self-
emulsification region. A series of SNEDDS formulations were prepared using labrasol: cremophor EL with a combination of peceol: ethyl oleate by 
using the simplex lattice design. Prepared formulation evaluated for refractive index, turbidimetric, droplet size, zeta potential and polydispersity 
index, self-emulsification, stability tests, viscosity and in vitro diffusion studies. 
Results: The best formula for SNEDDS in the current study were:  15% oil (peceol: ethyloleatein 1:1 ratio), 50% Labrasol and 35% Cremophor EL. 
All the SNEDDS batches globule size was found to be varied from 22.90±1.50 nm to 43.90±1.40 nm. and no significant variations in globule size 
were observed after 3 mo stability studies. All the batches % transparency was found to be varied from 95.40±1.40% to 99.50±1.10% and drug 
diffused in 10 min varied from 63.65±1.51% to 93.72±1.46 %.  
Conclusion: The data suggest the use of rosuvastatin calcium SNEDDS to offer the potential for delivery and it increases the aqueous solubility and 
bioavailability of the drug.  
Keywords: SNEDDS, Rosuvastatin Calcium, Simplex lattice design, Peceol, Ethyl Oleate, Labrasol, Cremophore EL. 
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INTRODUCTION 
Orally available drugs must be a sufficient soluble and permeable 
through the gastrointestinal tract. Almost two-thirds of the new drug 
candidates are poorly water-soluble, which is commonly associated 
with low bioavailability, high intra-and inter-subject variability, and 
lack of dose suitability. Lipid-based formulations offer the opportunity 
to enhance the absorption of lipophilic drugs. Being a nanosized, self-
nano emulsifying drug delivery system (SNEDDS) offers a strong 
alternative to the more conventional oral formulations of lipophilic 
compounds. SNEDDS are isotropic mixtures of natural or synthetic 
oils, solid or liquid surfactants, one or more hydrophilic solvents and 
cosolvents: surfactants that have forming fine oil-in-water emulsions 
upon mild agitation followed by dilution in aqueous media [1, 2]. 
The model drug for the current study had been selected from the 
biopharmaceutical classification system (BCS) class II. Rosuvastatin 
calcium is a lipid-lowering drug was an attractive candidate for the 
current study because it is a lipophilic compound with partition 
coefficient; log P = 4.81 and low aqueous solubility (0.00936 mg/ml). 
The current rosuvastatin calcium commercially marketed dosage 
forms is tablets and these show low (about 20%) and erratic oral 
bioavailability [3, 4]. The aim of the present study is bioavailability 
enhancement of rosuvastatin calcium and find the optimum formula 
of rosuvastatin calcium SNEDDS followed by characterization. 
MATERIALS AND METHODS 
Materials and reagents  
Rosuvastatin calcium was gifted by Mepro Pharmaceuticals Pvt. Ltd., 
Surendranagar, Gujarat, India. Peceol, Labrasol, Transcutol P, 
Labrafil M, Labrafil M, Lauroglycol FCC and Capryol 90 were gifted 
by Gattefosse India Pvt. Ltd, Mumbai, India. Cremophore EL was 
gifted from BASF India Ltd., Mumbai, India. Sefsol was gifted from 
Nikko Chemicals, Japan. Polyethylene glycol 400, Propylene glycol, 
Tween 80, Tween 20, Span 20, Span 80, Oleic acid, Castor oil, Olive 
oil, Cotton-seed oil, Sesame oil and Almond oil were purchased from 
Seva fine chemical ltd, Ahmedabad, Gujarat, India. Methanol AR 
grade was purchased from SD fine chem Ltd, Mumbai, India. All 
other materials and chemicals used were of either pharmaceutical or 
analytical grade. 
Solubility study and screening of surfactants, cosurfactant and oil 
Screening of surfactants and oil was done by the equilibrium 
solubility method. An excess quantity of rosuvastatin calcium was 
added to 2 ml of excipients and mixed in a vial. The mixtures in vials 
were shaken at 25±1.0 °C for 48 h using a rotary shaker (Remi, 
Mumbai, India). Then, mixtures were centrifuged at 5000 rpm for 15 
min. The supernatant was separated and the drug was extracted in 
methanol. The drug content was analyzed by using shimadzu 1700 
UV-visible spectrophotometer at 244 nm. Several trials were taken 
with different ratios of surfactants, cosurfactants and oils to select 
the proper combination of surfactant: cosurfactant: oil. Preliminary 
selection of 0.5 ml surfactant: cosurfactant: oil (Smix: oil) ratios were 
prepared and diluted with water by water titration method. From 
the different trails, ratios which gave clear emulsion on dilution 
were selected for further study [5, 6]. 
Drug excipient interaction study 
Drug excipient interaction study was carried out by differential 
scanning calorimetric (DSC). DSC thermograms of the rosuvastatin 
calcium and formulation were derived from a DSC with a thermal 
analysis performed by an automatic thermal analyzer system (DSC 
60, Shimadzu, Japan). The analysis was performed at a rate of 10 
°C/min from 50 °C to 250 °C under a nitrogen flow of 20 ml/min [7, 
8]. 
Development of pseudo-ternary phase diagram 
Pseudo ternary phase diagrams of oil, surfactant: cosurfactant (S: 
CoS) and water were developed using the water titration method. 
Aliquot of surfactant: cosurfactant mixture (Smix) mixed with oil at 
room temperature (25 °C). The ratio of Smix to oil was varied as 9:1, 
8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8 and 1:9 (%v/v). Deionized water was 
added in small increments (≤5% v/v) to the mixture of Smix/oil and 
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stirred in a vortex shaker for 2 min (Remi, Mumbai, India). 
Concentration of water at which turbidity to transparency and 
transparency to turbidity transitions occurred was derived from 
weight measurements. These values were used to determine the 
boundaries of the nanoemulsion domain corresponding to choose 
the value of oils and surfactant: cosurfactant mixing ratio. To 
determine the effect of rosuvastatin calcium on nanoemulsion 
boundary, phase diagrams were constructed with the drug. Pseudo 
ternary phase diagrams were plotted using Tri plot version 4.1.2 
[9-11]. 
Evaluation of rosuvastatin calcium SNEDDS 
Drug Content: Drug was extracted from SNEDDS by dissolving in 25 
ml methanol. Then the methanolic extract was separated out and 
drug content in methanolic extract was analyzed spectro-
photometrically UV Visible spectrophotometer (Shimadzu 1700) at 
244 nm, against the standard methanolic solution of Rosuvastatin 
calcium. 
Self-Emulsification Time: The emulsification time of SNEDDS was 
determined by USP-II, dissolution apparatus. Each formulation was 
added dropwise into 500 ml with purified water at 37˚C and 50 rpm. 
Emulsification time was assessed visually. 
Refractive Index: SNEDDS was added to 250 ml 0.1 N hydrochloric 
acid and 250 ml purified water at 50 rpm on a magnetic plate at 
ambient temperature. Then Refractive index of the system was 
measured by using an Abbe’s Refractometer [12, 13]. 
Turbidimetric: SNEDDS was added to 250 ml 0.1 N hydrochloric acid 
and 250 ml purified water at 50 rpm on a magnetic plate at ambient 
temperature. Turbidity of the system was measured by measuring % 
transmittance at 694 nm in the UV-Visible spectrophotometer. 
Droplet Size, Zeta Potential and Polydispersity Index (PDI): Droplet size 
and zeta potential were determined using Particle size analyzer 
(Zetatrac, Microtrac). It is controlled by Microtrac FLEX Operating 
Software Particle size analyzer uses a high-frequency AC electric field to 
oscillate the charged particles. The Brownian motion power spectrum is 
analyzed with the Modulated Power Spectrum (MPS) technique, a 
component of the power spectrum resulting from oscillating particles. 
Samples were diluted to 250 ml with purified water and placed into 
cuvette to measure particle size, PDI and zeta potential [14, 15]. 
Dilution and Aqueous Phase Composition: Robustness of SNEDDS to 
the dilution and effect of aqueous phase composition were studied. 
Optimized formulation was dispersed in 250 ml of distilled water 
and 0.1 N HCL with gentle stirring. Resulting emulsion was kept at 
25±2 °C. Emulsion was evaluated for drug precipitation, phase 
separation and size over the period of 24 h. 
Viscosity: Viscosity was measured by using Brookfield viscometer 
(Middleboro, USA) at 25 °C. Spindle S61 was selected for the 
measurement of various formulations. Viscosity of SNEDDS was 
measured at 30 rpm before dilution and after dilution with aqueous 
phase (250 ml). 
In vitro Diffusion Studies: In vitro diffusion studies were carried out 
by dialysis technique. In this method, one end of dialysis membrane 
tubing (12 cm in length) was with thread and diluted SNEDDS was 
filled in it. Then, another end of the tubing was also secured with 
thread and it was allowed rotating freely in the dissolution vessel of 
USP-II, dissolution test apparatus (Electrolab TDT-08L, USP). 
Dissolution apparatus contained 250 ml pH 6.8 phosphate buffer 
maintained at 37±0.5 °C and stirred at 50 rpm. Aliquots were 
collected periodically and replaced with fresh dissolution medium. 
Aliquots, after filtration through Whatman filter paper (No. 41), 
were analyzed spectrophotometrically at 244 nm for drug content 
[16, 17]. 
Stability Study: Chemical and physical stability of rosuvastatin 
calcium SNEDDS were assessed at 40±2 °C/75±5% RH and 25±3 °C 
as per ICH guidelines. It was stored in a glass vial and subject to a 
stability chamber over a period of 3 mo. Samples were withdrawn 
after 3 mo and assessed for physical appearance, dispersion time, % 
transmittance, viscosity and drug content. 
Accelerated Stability Tests by Centrifugation and Freeze-Thaw Cycle: 
Rosuvastatin calcium SNEDDS were diluted with 250 ml aqueous 
phases (distilled water and 0.1 N HCL) and centrifuged (Remi, 
Mumbai, India) at 5000 rpm for 30 min. In addition, it was subjected 
to a freeze-thaw cycle by storing it at-20 °C for 24 h and then for 
another 24 h at 40 °C. Nanoemulsions were observed visually for 
phase separation and drug precipitation, whereas their physical 
stability was assessed by measuring globule size before and after 
centrifugation and freeze-thaw cycle [18, 19]. 
Optimization of rosuvastatin calcium SNEDDS by using simplex 
design 
A simplex lattice design was used to optimize for SNEDDS. In this 
design, three factors were evaluated by changing their 
concentrations simultaneously and keeping their total concentration 
constant. The simplex lattice design is a three-component system 
and it’s represented by an equilateral triangle as shown in fig 1. 
Seven batches of SNEDDS were prepared, including three vertexes 
(A, B, C), three half-way points between vertices (AB, AC, BC), and 
one center point (ABC). Code representations of formulation with 
actual and transformed values are shown in table 1. The 
concentrations of surfactant, cosurfactant and oil were selected as 
independent variables. Mean globule size, percent transparency and 
amount of drug diffuse through dialysis membrane in 10 min were 
taken as responses. The responses of seven formulations were used 
to fit an equation for the simplex lattice model which can predict 
properties of all possible formulations using of Design Expert 8.0.5 
[20-22]. 
 
Table 1: Simplex lattice design of rosuvastatin calcium SNEDDS 
Formulation Code Concentration (Transformed value) 
Surfactant Cosurfactant Oil 
F1 A 1 0 0 
F2 B 0 1 0 
F3 C 0 0 1 
F4 AB 0.5 0.5 0 
F5 AC 0.5 0 0.5 
F6 BC 0 0.5 0.5 
F7 ABC 0.33 0.33 0.33 
Code Transformed value Actual value in % 
A (Surfactant Labrasol) 0 50 
1 65 
B (Cosurfactant-Cremophor EL) 0 20 
1 35 
C {Oil (1:1)-Peceol: Ethyloleate} 0 15 
1 30 
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RESULTS AND DISCUSSION 
Solubility study and screening of surfactants, cosurfactant and oil  
SNEDDS consists of a mixture of oil, surfactant, cosurfactant and 
drug. When SNEDDS introduced to an aqueous phase, the mixture 
should form a clear and monophasic at room temperature. It should 
have good solvent properties that allow the drug to be present in 
solubilised form. The results of the solubility of rosuvastatin calcium 
in various vehicles were shown in fig. 2 and 3. Rosuvastatin calcium 
had the highest solubility in oleic acid with comparison to other lipid 
vehicles. Among oils, olive oil, cottonseed oil and almond oil were 
having miscibility problems with the selected surfactants, as well as 
they shown lesser solubility of rosuvastatin calcium, so they were 
rejected. Rosuvastatin calcium had the highest solubility in 
Transcutol P as compare to other surfactant and cosurfactant. 
Further Morelabrasol, Cremophor EL and Propylene glycol also 
showed very high solubility of rosuvastatin calcium. In contrast, 
Lauroglycol FCC, Labrafil M2125 CS, Labrafil M 1944 Cs, Tween 80, 
Tween 20 and Span 80 were rejected due to a comparatively lesser 
solubility. Lutrol F 68 was having a solid-state so if it was used 
precipitation might have occurred on storage, so it was also rejected. 
From this study, it reveals that transparent emulsion was not formed 
by using Sefsol 218, Oleic acid, Castor oil, Sesame oil with different 
surfactants and cosurfactants. Transparent emulsions were formed 
by using Peceol: Labrasol, Propylene glycol: Ethyl oleate with 
Cremophor EL but these, combinations showed phase separation on 
higher dilutions. On the other hand Ethyl oleate with Cremophor EL: 
Propylene glycol, formed gel-like structures when it diluted with 
water. So the combination of Labrasol: Cremophor EL and Peceol: 
ethyl oleate was tried. Finally, based upon clarity of emulsion, 
Peceol: Ethyl oleate and Labrasol: Cremophor EL was selected for 
further investigation. 
 
Fig. 1: Equilateral triangle representing simplex lattice design for 
three components 
 
Fig. 2: Solubility of rosuvastatin calcium in various oils 
 
Fig. 3: Solubility of rosuvastatin calcium in various surfactants 
 
 
Fig. 4: DSC spectra of formulation mixture of drug, oil, surfactant 
and cosurfactant (a), pure drug (b) 
 
Drug-excipient interaction study 
The DSC results provided both qualitative and quantitative 
information about the physicochemical state of the drug present in 
the formulation. The thermogram of rosuvastatin calcium showed a 
melting endothermic peak at 85.34 °C and a formulation mixture 
containing rosuvastatin calcium showed a melting endothermic peak 
at 80.97 ⁰C as shown in fig. 4. The thermogram of the drug does not 
change after mixing with oil, surfactant and cosurfactant indicates 
the compatibility of oil, surfactant and co-surfactant with the drug. 
The peaks in both the thermogram show that there is no significant 
interaction between drug and excipients [23, 24]. 
Pseudo ternary phase diagram 
Pseudo ternary phase diagrams were constructed to identify the 
self-nano emulsifying regions and optimize the concentration of oil 
as shown in fig 5. The efficiency of emulsification was good when 
Labrasol: Cremophor EL concentration was more than 50% in a 
formulation. It was observed that increasing concentration of 
surfactants also increased the spontaneity of the self-emulsification 
region. Therefore, a higher concentration of surfactant higher self-
emulsifying region in phase diagrams. The ratio of surfactant: 
cosurfactant was very effective in a stable and efficient SNEDDS 
formation. The phase diagrams were constructed at ratio of 
surfactant: cosurfactant 1:1, 2:1, 3:1 and 4:1. However, the stability 
of self-emulsifying droplets 1:1, 3:1 and 4:1 was decreased and 
precipitation after a few hour. So, ratio of 2:1 was chosen in the 
formulation. To determine the effect of drug addiction on the nano-
emulsion boundary, phase diagram was constructed in the presence 
of the drug. No significant changes were observed in phase diagram 
regions after drug loading [25, 26]. 
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Fig. 5: Pseudo-ternary phase diagrams (A) S: CoS ratio 1:1 (B) S: CoS ratio 2:1 (C) S: CoS ratio 3:1 (D) S: Cos ratio 4:1 
 
Optimization of rosuvastatin calcium SNEDDS by using simplex 
design 
Simplex lattice design was used to optimize the rosuvastatin calcium 
SNEDDS. The concentrations of surfactant (A), cosurfactant (B) and 
oil (C) were chosen as the independent variables. The equation for 
simplex lattice model is described as follows:  
R = βaA+βbB+βcC+βabAB+βacAC+βbcBC+βabcABC 
Where R is the dependent variable and βi is the estimated coefficient 
for the factor (A/B/C). The major effects (A, B, and C) represent 
average results of changing one factor at a time from its low to high 
value, the interactions AB, BC, AC, and ABC. The results of their mean 
droplet size (R1), % transparency (R2) and the amount of drug 
diffused in 10 min (R3) were given in table 2 [26, 27]. 
Mean globule size  
R1 = 43.90A+22.95B+41.00C-4.50AB+16.20AC-3.50BC-188.76 ABC 
All the SNEDDS batches globule size was found to be varied 
from 22.90±1.50 nm to 43.90±1.40 nm. As seen from fig. 6 (I), the 
Contour plot reveled that means globule size is less when the 
amount of B is increased. Here, it can be predicted that Cremophor 
EL has the highest effect on mean globule size. Additionally, βab, βbc, 
and βabc had a negative value which showed a synergistic effect on 
mean globule size. βac had an antagonistic effect on mean globule 
size it had a positive value. 
% Transparency 
R2 = 95.50A+99.50B+95.80C+3.28AB-1.00AC+1.40BC+28.56ABC 
All the SNEDDS batches % transparency was found to be varied 
from 95.40±1.40% to 99.50±1.10%. As saw from fig 6 (II), the 
contour plot revealed that B has highest effect on % transparency. 
Additionally, βac had a negative value which showed an antagonistic 
effect of % transparency. βab, βbc, and βabc had a synergistic effect 
on % transparency because they had a positive value. 
Amount of drug diffused in 10 min 
R3 = 67.39A+93.72B+68.81C+29.70AB-17.80AC+0.58BC-173.22ABC 
All the formulation showed drug diffused in 10 min varied 
from 63.65±1.51% to 93.72±1.46 %. As saw from fig 6 (III), the contour 
plot revealed that B has the highest effect on the amount of rosuvastatin 
calcium in 10 min. Additionally, βac and βabc had a negative value which 
showed an antagonistic effect on rosuvastatin calcium diffused in 10 min. 
βab and βbc had a synergistic effect on rosuvastatin calcium diffused in 
10 min because they had a positive value. 
  
Table 2: Runs and measured responses of rosuvastatin calcium SNEDDS by using simplex design 
Formulation code Formulation components Mean globule 
size (nm) (R1) 
% Transparency 
(R2) 
% Drug diffused 
in 10 min (R3) Surfactant (A) Cosurfactant (B) Oil (C) 
F1 1 0 0 43.90±1.40 95.50±1.60 67.39±1.54 
F2 0 1 0 22.90±1.50 99.50±1.10 93.72±1.46 
F3 0 0 1 41.50±2.60 95.80±1.30 68.81±2.10 
F4 0.5 0.5 0 32.30±1.60 98.32±2.00 87.98±1.40 
F5 0.5 0 0.5 46.50±2.80 95.40±1.40 63.65±1.51 
F6 0 0.5 0.5 31.10±1.50 98.00±2.10 81.41±1.78 
F7 0.33 0.33 0.33 29.87±1.40 98.40±1.30 71.61±2.10 
n=6 
 
Table 3: Summary of regression analysis of significant factors 
Responses  Coefficients of parameters 
 βa βb Βc βab βac βbc βabc R2 
Mean globule size  43.90 22.95 41.00 -4.50 16.20 -3.50 -188.76 1 
% Transparency 95.50 99.50 3.28 3.28 -1.00 1.40 28.56 1 
Amount of drug diffused in 10 min 67.39 93.72 68.81 29.70 -17.80 0.58 -173.22 1 
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Table 4: Analysis of variance (ANOVA) of the dependent variable 
Source of variation DF SS MS F P 
Mean globule size 
Regression 1 32.32 32.32 63660000.0 <0.001 
% Transparency 
Regression 1 0.74 0.74 63660000.0 <0.001 
% Amount of drug diffused in 10 min 
Regression 1 27.22 27.22 63660000.0 <0.001 
 
 
Fig. 6: Contour plots (I) mean globule size (ii) % transparency (iii) amount of drug diffused in 10 min (iv) superimposed ternary contour 
plot of the three responses 
 
The Summary of regression analysis of significant factors and results 
of ANOVA shown in table 3 and table 4 respectively. It suggested that 
F, as well as P values, are significant. Counter plots as shown in fig 6, it 
reveals that an inverse relationship exists between mean globule size 
and % transparency. As the globule size of SNEDDS increases, % 
transparency decreases. Direct relationship exists between % 
transparency and % amount of drug diffusion. As the % transparency 
of formulation increases, the amount of rosuvastatin calcium diffused 
in 10 min were also increases. In order to obtain both high % 
transparency, high amount of rosuvastatin calcium diffused in 10 min 
and smallest possible mean globule size, the appropriate ratio of 
components was chosen for the optimized formulation, which 
consisting of oil (15%), surfactant (35%), cosurfactant (50%). 
Validation of design  
One extra checkpoint was taken and the checkpoint batch was 
prepared as shown in table 5. The checkpoint batch was evaluated 
for all three dependent variables. The practically obtained responses 
of the checkpoint batch were compared with the calculated 
responses from the simplex equations shown in table 6. Practically, 
obtained responses are closer to the predicted response. Closeness 
of the value justifies the validation of design [28, 29]. 
 
Table 5: Checkpoint prediction 
Batch code Variable level 
Coded value Actual value in % 
A B C A B C 
CP 0.342 0.391 0.267 57.13 25.87 19.0 
 
Table 6: Evaluation of checkpoint batches and comparison with the predicted value 
Variable Predicted response Practical response 
Mean globule size 28.70 nm 29.01±1.03 nm 
 % Transparency 98.65 % 98.25±0.67% 
% Amount of drug diffused in 10 min 74.03 % 74.9±1.44% 
n=6 
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Table 7: Evaluation of drug content, self-emulsification time, refractive index% and %transmittance of SNEDDS 
Batch Drug content (%) Self-emulsification time (s) Refractive index % Transmittance 
0.1 N HCL Distilled water 0.1 N HCL Distilled water  
F1 098.91±0.51 24.67±4.18 1.41±0.13 1.40±0.06 43.85±1.21 95.50±1.21 
F2 099.63±0.21 12.67±3.73 1.33±0.11 1.33±0.07 93.64±2.14 99.50±0.43 
F3 098.07±0.55 15.33±3.06 1.38±0.07 1.37±0.13 02.30±0.12 95.80±1.33 
F4 100.35±0.44 19.33±2.57 1.40±0.08 1.38±0.11 87.15±2.01 98.32±1.14 
F5 099.37±0.83 17.00±2.96 1.39±0.09 1.34±0.06 03.10±0.10 95.40±1.15 
F6 102.07±0.25 20.33±1.90 1.37±0.05 1.35±0.04 61.10±1.33 98.00±2.16 
F7 097.77±0.45 23.67±0.58 1.40±0.10 1.38±0.05 42.90±1.21 98.40±2.13 
n=6 
 
Selection of optimized batch  
Batch F2 was selected as an optimized batch in order to obtain high % 
transparency and higher % diffusion and the smallest mean globule 
size. The appropriate ratio of components for optimized formulation 
F2 was, oil (15%), surfactant (35%), cosurfactant (50%). 
Evaluation of rosuvastatin calcium SNEDDS 
The results of all batches of SNEDDS showed drug content variation 
range from 98.91% to 102.07%. Emulsification time is an important 
parameter for SNEDDS and all the formulation was prepared 
nanoemulsion within 24 s. Refractive index and % transmittance of 
various formulations were shown in table 7. Batch F2 had refractive 
index and % transmittances are similar in water, so it’s proving the 
transparency of the system. Droplet size distribution is a critical 
factor to evaluate SNEDDS. The smaller droplets have a larger 
interfacial surface area that will be provided for drug absorption. 
The optimized formulation (F2) has found droplet size 22.95±1.50 
nm and it’s shown in fig. 7. Generally, an increase of electrostatic 
repulsive forces between droplets prevents the coalescence of 
droplets. On the contrary, a decrease of electrostatic repulsive forces 
will cause phase separation. Rosuvastatin calcium SNEDDS (F2) was 
diluted with distilled water and resulted in zeta potential was found-
8.40±0.02mV. According to the study, positively charged droplets 
could have better interaction with the mucus of the gastrointestinal 
tract, because intestinal cell interior carry negative charges with the 
presence of mucosal fluid. Here, F2 formulation has a positive 
potential, it was likely to facilitate intestinal absorption of 
rosuvastatin calcium. [30, 31] Effect of Dilution and aqueous phase 
composition results indicated that SNEDDS can be diluted up to 
1,000 fold without any phase separation or drug precipitation and 
it’s remained stable over a 24 h. Aqueous phase composition also did 
not affect the physical stability of the resulting emulsion. Viscosity 
data were shown in table 8. It was observed that before dilution the 
formulation having higher viscosity and after dilutions with water 
up to 250 ml the emulation viscosity near to the water. 
 
 
Fig. 7: Droplet size analysis of SNEDDS formulation (F2) 
 
Fig. 8: Diffusion profile of various SNEDDS formulations 
 
Table 8: Evaluation of viscosity, particle size, zeta potential and % PDI of SNEDDS 
Batch Viscosity (cps) Particle size (nm) Zeta potential PDI 
Before dilution After dilution (distilled water) 
F1 216.44±2.51 1.18±0.07 43.90±0.11 -0.49±0.03mV 0.063±0.01 
F2 315.56±3.56 1.27±0.11 22.95±0.44 -8.40±0.02mV 0.692±0.03 
F3 210.44±0.46 1.08±0.11 41.44±0.64 -0.49±0.03mV 0.127±0.01 
F4 265.55±3.55 1.20±0.17 32.38±0.36 -0.49±0.01mV 0.100±0.02 
F5 262.55±1.33 1.19±0.15 46.58±0.75 -0.49±0.02mV 0.118±0.02 
F6 213.67±3.61 1.23±0.15 31.18±0.25 -0.49±0.03mV 0.067±0.02 
F7 247.78±0.67 1.25±0.11 29.87±0.66 -0.49±0.03mV 0.190±0.01 
n=6 
 
In vitro diffusion studies 
The drug diffusion profile of different SNEDDS is shown in fig 8. 
Order of drug diffusion through the dialysis membrane was 
F2>F4>F6>F7>F3>F1>F5. It shows that increasing the droplet 
size of nanoemulsion decrease the diffusion rate of the drug. 
Optimized batch F2 was given more than 95% release in 15 min. 
It suggests that rosuvastatin calcium dissolved in SNEDDS and 
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diffused due to the small droplet size. SNEDDS was given a faster 
rate of drug release in the aqueous phase which affects 
bioavailability. 
Stability studies of rosuvastatin calcium SNEDDS 
No change in physical parameters such as homogeneity and clarity of 
SNEDDS was observed during stability studies. The stability data of 
rosuvastatin calcium SNEDDS at stated storage conditions is shown in 
table 9. Interestingly, it was shown that no decline in rosuvastatin 
calcium content which was observed at the end of three months 
indicating that rosuvastatin calcium remained chemically stable in 
SNEDDS. Furthermore, other parameters such as self nanoemulsion 
efficiency, % transmittance viscosity and dispersion time remained 
unchanged at all storage conditions during the entire period of study. 
 
Table 9: Stability data of rosuvastatin calcium SNEDDS batch F2 
Time (mo) Storage conditions Drug content (%w/w) Viscosity (cps) % Transmittance Dispersion time (sec) 
Before dilution After dilution 
0 25±3 °C 99.63±0.54 315.54±1.64 1.90±0.43 99.50±0.21 13±1 
40±2 °C/75±5% 99.63±0.24 312.44±1.87 1.87±0.64 99.50±1.11 12±2 
1 25±3 °C 99.47±1.76 316.64±2.97 1.92±0.65 99.35±1.34 13±1 
40±2 °C/75±5% 99.41±0.24 312.67±0.34 1.89±0.76 99.14±3.71 14±2 
2 25±3 °C 99.46±0.76 316.27±1.25 1.92±0.34 99.22±1.57 13±1 
40±2 °C/75±5% 99.37±1.23 315.34±0.65 1.90±0.76 99.16±0.45 13±1 
3 25±3 °C 99.41±0.76 315.75±1.86 1.88±0.54 99.15±1.75 12±2 
40±2 °C/75±5% 99.30±0.62 314.67±0.45 1.87±0.23 99.18±1.24 13±1 
n=6 
 
Accelerated stability study by centrifugation and freeze-thaw cycle 
The effect of centrifugation and freeze-thaw cycling on emulsion is 
shown in table 10. Accelerated tests were carried under stress 
conditions. Optimized SNEDDS (F2) did not exhibit any drug 
precipitation and phase separation after centrifugation. Similarly, it 
survived freeze-thaw cycling and it was reconstituted without any 
phase separation or drug precipitation. 
 
Table 10: Accelerated stability of SNEDDS 
Accelerated stability Parameter Formulation code 
F1 F2 F3 F4 F5 F6 F7 
Centrifugation Phase separation Slight* No* No* No* Slight* No* Slight* 
Drug precipitation No* No* No* No* No* No* No* 
Freeze-thaw cycle Phase separation No* No* No* No* No* No* No* 
Drug precipitation No* No* No* No* No* No* No* 
* = (same result was noticeable in all 6 formulation) n=6 
 
CONCLUSION 
The bioavailability enhancement of most oral lipid-based 
formulations depends on the ability of the oil vehicle to maintain the 
drug in solution after dispersion. The SNEDDS was explored 
successfully for oral delivery of poorly soluble drug rosuvastatin 
calcium. SNEDDS are isotropic mixtures made up of oil, surfactant, 
cosurfactant and cosolvent. In an aqueous environment, a 
homogeneous, isotropic and thermodynamically stable 
nanoemulsion formed. The formulation of SNEDDS was optimized by 
a simplex lattice design. Solubility study was showed the highest 
solubility of rosuvastatin calcium in Transcutol P as compare to 
other materials. Pseudo ternary phase diagrams were constructed to 
identify the efficient self-emulsification region. SNEEDS had also 
shown that after dilution there was no precipitation and phase 
separation found. No significant variations in globule size were 
observed after the Stability study. In vitro diffusion studies revealed 
that the release of rosuvastatin calcium from SNEDDS was faster. 
Nonetheless, there is a clear need for developing methods for 
tracking the solubilization state of the drug in vivo. 
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